|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Acetylene tetrabromide | CAS 79-27-6 | ||
| CHBr2CHBr2 | RTECS KI8225000 | ||
|
Synonyms & Trade Names Symmetrical tetrabromoethane; TBE; Tetrabromoacetylene; Tetrabromoethane; 1,1,2,2-Tetrabromoethane |
DOT ID & Guide 2504 159 |
||
|
Exposure Limits |
NIOSH REL: See Appendix D | ||
| OSHA PEL: TWA 1 ppm (14 mg/m3) | |||
| IDLH 8 ppm | Conversion 1 ppm = 14.14 mg/m3 | ||
|
Physical Description Pale-yellow liquid with a pungent odor similar to camphor or iodoform. [Note: A solid below 32°F.] |
|||
|
MW: 345.7 |
BP: 474°F (Decomposes) |
FRZ: 32°F |
Sol: 0.07% |
|
VP: 0.02 mmHg |
IP: ? |
|
Sp.Gr: 2.97 |
|
Fl.P: NA |
UEL: NA |
LEL: NA |
|
| Noncombustible Liquid | |||
|
Incompatibilities & Reactivities Strong caustics; hot iron; reducing metals such as aluminum, magnesium & zinc |
|||
|
Measurement Methods NIOSH 2003 |
|
Personal Protection & Sanitation Skin: Prevent skin contact Eyes: Prevent eye contact Wash skin: When contaminated Remove: When wet or contaminated Change: No recommendation |
First Aid (See procedures) Eye: Irrigate immediately Skin: Water flush promptly Breathing: Respiratory support Swallow: Medical attention immediately |
|
Respirator Recommendations
OSHA Up to 8 ppm: (APF = 10) Any supplied-air respirator/(APF = 50) Any self-contained breathing apparatus with a full facepiece Emergency or planned entry into unknown concentrations or IDLH conditions: (APF = 10,000) Any self-contained breathing apparatus that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode/(APF = 10,000) Any supplied-air respirator that has a full facepiece and is operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained positive-pressure breathing apparatus Escape: (APF = 50) Any air-purifying, full-facepiece respirator (gas mask) with a chin-style, front- or back-mounted organic vapor canister/Any appropriate escape-type, self-contained breathing apparatus |
|
| Exposure Routes inhalation, ingestion, skin and/or eye contact | |
| Symptoms Irritation eyes, nose; anorexia, nausea; headache; abdominal pain; jaundice; leukocytosis (increased blood leukocytes); central nervous system depression | |
|
Target Organs
Eyes, respiratory system, liver, central nervous system |
|
| See also: INTRODUCTION |